TickerFacts.

Scinai Immunotherapeutics Ltd. (SCNI): Cost of Revenue

Annual figures by period end, from SEC filings.

$3.96M
Year ended 2025-12-31
2024-12-31: $1.24M2025-12-31: $3.96M$3.96M
2024-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$3.96M+220.1%2026-04-01, From 2025-01-01
2024-12-31$1.24Mn/a2026-04-01, From 2024-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$3.96M+220.1%
Outlook Therapeutics, Inc. (OTLK)2025-09-30$1.36Mn/a
Pluri Inc. (PLUR)2026-06-30$563.0K-17.4%
Humacyte, Inc. (HUMA)2025-12-31$9.70Mn/a
Dyadic International Inc (DYAI)2025-12-31$2.32M+94.2%
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$931.0K+10.3%
Alpha Cognition Inc. (ACOG)2025-12-31$603.4Kn/a
Zivo Bioscience, Inc. (ZIVO)2024-12-31$108.3K+575.0%
VivoSim Labs, Inc. (VIVS)2026-03-31$0-100.0%

Compare SCNI, OTLK, PLUR, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗